Analysts forecast that Iovance Biotherapeutics (NASDAQ:IOVA) will announce earnings per share (EPS) of ($0.32) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.34). Iovance Biotherapeutics also posted earnings of ($0.32) per share in the same quarter last year. The business is expected to report its next quarterly earnings results on Tuesday, August 7th.
On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.27) per share for the current year, with EPS estimates ranging from ($1.40) to ($1.17). For the next financial year, analysts expect that the business will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.52) to ($1.21). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.02).
Shares of IOVA stock traded down $0.10 during trading hours on Thursday, reaching $16.35. The stock had a trading volume of 802,846 shares, compared to its average volume of 972,358. Iovance Biotherapeutics has a twelve month low of $15.20 and a twelve month high of $16.50. The stock has a market cap of $1.37 billion, a PE ratio of -11.60 and a beta of 5.94.
Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its stake in shares of Iovance Biotherapeutics by 2.6% in the 4th quarter. Deutsche Bank AG now owns 140,536 shares of the biotechnology company’s stock worth $1,123,000 after purchasing an additional 3,627 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Iovance Biotherapeutics by 9.9% in the 1st quarter. Wells Fargo & Company MN now owns 54,832 shares of the biotechnology company’s stock worth $926,000 after purchasing an additional 4,957 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Iovance Biotherapeutics by 12.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 45,817 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 5,110 shares during the last quarter. Ellington Management Group LLC grew its stake in shares of Iovance Biotherapeutics by 39.1% in the 4th quarter. Ellington Management Group LLC now owns 19,200 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 5,400 shares during the last quarter. Finally, American International Group Inc. grew its stake in shares of Iovance Biotherapeutics by 13.6% in the 1st quarter. American International Group Inc. now owns 47,114 shares of the biotechnology company’s stock worth $796,000 after purchasing an additional 5,644 shares during the last quarter. 64.85% of the stock is currently owned by hedge funds and other institutional investors.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.